Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
RegulatoryapprovedItvisma®Positive
AI Analysis
Summary
Novartis announced European Commission approval of Itvisma® (onasemnogene abeparvovec) for treating spinal muscular atrophy with SMN1 gene mutations in patients aged 2 years and older. This regulatory milestone expands the drug's indication across pediatric and adult populations in Europe.
Outcome Details
European Commission approval for treatment of children 2 years and older, teens and adults with 5q SMA
Importance:8/10
Sentiment:
0.90
regulatory approvalEuropespinal muscular atrophygene therapypediatric
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 2, 2026 5:00 AM